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Abstract
Background: Colorectal cancer usually gives rise to a specific anti-tumor immune response, but for unknown reasons the
resulting immunity is not able to clear the tumor. Recruitment of activated effector lymphocytes to the tumor is important
for efficient anti-tumor responses, while the presence of regulatory T cells (Treg) down-modulate tumor-specific immunity.
We therefore aimed to determine homing mechanisms and activation stage of Treg and effector T cell infiltrating colon
tumors compared to cells from the unaffected mucosa in patients suffering from colon adenocarcinoma.
Methodology/Principal Findings: Lymphocytes were isolated from unaffected and tumor mucosa from patients with colon
adenocarcinoma, and flow cytometry, immunohistochemistry, and quantitative PCR was used to investigate the homing
mechanisms and activation stage of infiltrating Treg and conventional lymphocytes. We detected significantly higher
frequencies of CD25
highFOXP3
+CD127
low putative Treg in tumors than unaffected mucosa, which had a complete
demethylation in the FOXP3 promotor. Tumor-associated Treg had a high expression of CTLA-4, and some appeared to be
antigen experienced effector/memory cells based on their expression of aEb7 (CD103). There were also significantly fewer
activated T cells and more CTLA-4
+ conventional T cells susceptible to immune regulation in the tumor-associated mucosa.
In contrast, CD8
+granzyme B
+ putative cytotoxic cells were efficiently recruited to the tumors. The frequencies of cells
expressing a4b7 and the Th1 associated chemokine receptor CXCR3 were significantly decreased among CD4
+ T cells in the
tumor, while frequencies of CD4
+CCR4
+ lymphocytes were significantly increased.
Conclusions/Significance: This study shows that CCR4
+CTLA4
hi Treg accumulate in colon tumors, while the frequencies of
activated conventional Th1 type T cells are decreased. The altered lymphocyte composition in colon tumors will probably
diminish the ability of the immune system to effectively attack tumor cells, and reducing the Treg activity is an important
challenge for future immunotherapy protocols.
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Introduction
Colorectal cancer (CRC) is one of the most common malignant
diseases with an annual incidence of 945 000 cases worldwide and
an annual mortality of about 500 000 [1]. Cytotoxic T
lymphocytes (CTL), supported by cytokine-producing Th1 cells,
are one of the most important effectors mechanisms in immunity
against tumors [2]. However, to be effective, tumor-specific
lymphocytes must be able to leave the circulation and enter into
the tumor. Lymphocyte extravasation from blood to tissues is a
multi-step process involving transient interactions between selec-
tins and their carbohydrate antigens, followed by chemokine
binding to specific receptors and integrin activation, leading to
firm arrest and transendothelial migration [3,4]. Integrin a4b7 is
the major mediator of lymphocyte homing to healthy gastrointes-
tinal tissues and binds to mucosal addressin cellular adhesion
molecule-1 (MAdCAM-1), expressed on endothelial cells in the
gastrointestinal tract [5]. L-selectin binds to peripheral node
addressin (PNAd), expressed by high endothelial venules in
secondary lymphoid tissues, and mediates homing of naı ¨ve and
central memory cells to these tissues [6,7]. In addition, chemokine
production in the tissue also contributes to differential tissue
distribution of migrating lymphocytes.
Tumors have developed several mechanisms by which they can
escape the host immune response [8]. The induction of so-called
regulatory T cells (Treg) in many types of cancer disease probably
also contribute to tumor immune evasion [9,10,11]. Treg are
suppressive CD4
+CD25
hiFOXP3
+CD127
low T cells, acting on
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e30695conventional T cells in a cell-cell contact-dependent manner [12].
The precise mechanisms of Treg mediated suppression have not
yet been fully characterized, but the suggested mediators include
CTLA-4 and Granzyme B [13,14]. Furthermore, the tumor
microenvironment may influence endothelial differentiation and
function [15,16] and we have recently shown a shift in endothelial
adhesion molecule expression in gastric adenocarcinomas. The
tumor-associated mucosa had a decrease in MAdCAM-1
+ and
increase in PNAd
+ blood vessels compared to in the unaffected
mucosa and also increased production of the CCR4 ligand
CCL17. These findings were correlated to increased frequencies of
L-selectin
+CCR4
+ Treg and fewer activated lymphocytes in the
tumor-associated mucosa [17,18].
Treg have also been shown to accumulate in colon tumors,
especially those associated with microsatellite instability, and in
the circulation of patients with CRC [19,20,21,22,23,24], and
several studies actually show that high intratumoral Treg
frequencies or low CD3/FOXP3 ratios correlate with improved
prognosis [19,25,26,27,28]. This is in contrast to most other
tumor types, where increased Treg frequencies correlate with a
poor prognosis [9,10,11]. To elucidate the effect of Treg
accumulation on local immune cell function and recruitment,
we explored the activation stage, as well as the homing
mechanisms of lymphocytes in human colon adenocarcinomas,
and compared that to the adjacent unaffected mucosa. Our
results show that CCR4
+CTLA4
hi Treg accumulate in colon
tumors, while the frequencies of activated conventional Th1 type
T cells are decreased. The altered lymphocyte recruitment to
colon tumors will probably contribute to the ability of the tumor
to avoid immune mediated elimination.
Results
Lymphocyte subsets in tumors and unaffected colonic
mucosa
Lamina propria lymphocytes (LPL) were isolated from tumor
and unaffected mucosa from patients undergoing colectomy, and
analysis of surface molecules defining T cells, B cells, and NK cells
was carried out using flow cytometry. The distribution of CD4
+
and CD8
+ T cells was similar in the two types of tissue, both total
frequencies and frequencies of CD45RO
+ memory subsets.
Similar and low frequencies of CD56
+CD3
2 NK cells were also
detected. In contrast, CD19
+ B cells were significantly decreased in
the tumor compared to the unaffected colonic mucosa (p,0.01,
data not shown).
To examine the presence of putative Treg we analyzed the
frequencies of CD25
high cells in the CD4
+ LPL populations. The
frequencies of CD4
+CD25
high T cells in the tumors were
significantly higher (p,0.001, fig. 1A) compared to unaffected
colonic mucosa from the same patients. The CD25
highcells were
invariably FOXP3
+ and CD127
low, which to date is the best
combination of markers to identify putative Treg [29] (Fig. 1B).
Since FOXP3 can be transiently expressed by human conven-
tional T cells following stimulation, we analyzed if the colonic
FOXP3
+ cells were stably expressing FOXP3, by assessing the
methylation status of the FOXP3 promoter region using
methylation-sensitive single nucleotide primer-extension analysis
(Ms-SNUPE). There was an almost complete demethylation of the
FOXP3 promoter in the CD4
+FOXP3
+ cells from both the tumor
and unaffected tissue (Fig. 1D), indicating that they stably express
FOXP3. CD4
+FOXP3
2 cells from both unaffected colonic tissue
and tumors had a lower demethylation than the CD4
+FOXP3
+
cells (range 51–100% and 53–74% in the tumor and unaffected
tissue, respectively; Fig. 1D).
Localization of T cells in tumor and unaffected mucosa
We also visualized CD4
+ and CD8
+ T cells as well as Treg in
tumor and unaffected mucosa in situ using immunofluorescence.
The unaffected mucosa had large numbers of CD4
+ cells scattered
throughout the lamina propria (Fig. 2A), whereas the submucosa
was clear of immune cells. CD8
+ cells were present in lower
numbers and seen in both the lamina propria and in-between
epithelial cells (Fig. 2C). Treg were present in low numbers in the
lamina propria. In the tumor, T cells were seen in lamina propria-
like parts of the tissue, where CD4
+, CD8
+ and Tregs were co-
localized (Fig. 2B and D). On the other hand, all three T cell
populations only rarely infiltrated among the tumor cells. Treg
were more frequent in the tumor tissue than unaffected tissue, and
sometimes closely associated with CD4
+ or CD8
+ cells, possibly
executing their regulatory effect (Fig. 2G).
Activation and differentiation state of LPL from tumor
and unaffected mucosa
To determine activation and differentiation stage of the T cells
present in tumors and unaffected tissue, flow cytometry was used
to analyse expression of CD45RA, CD69, CTLA-4, and
Granzyme B on freshly isolated LPL. Recently activated CD69
+
T cells were relatively frequent in the unaffected lamina propria,
but present in significantly lower numbers in the tumor (Fig. 3A).
There were also higher frequencies of CD4
+CD25
int activated cells
in the unaffected than in the tumor-associated mucosa (Fig. 1A
and C). The distribution of naı ¨ve, CD45RA
+, CD4
+ and CD8
+
cells was similar in the tumor and the surrounding mucosa (data
not shown). However, higher frequencies of CD8
+Granzyme B
+
cells, presumably differentiated CTL, were present in the tumor
than the unaffected tissue (Fig. 3B). Still, the ratio of CD8
+Gran-
zyme B
+ cells to CD4
+CD25
hi Treg cells was significantly higher
(p,0.01) in the unaffected then the tumor mucosa (Fig. 3E).
Granzyme B has also been described as an effector molecule used
by Treg [14], but in our material conventional CD4
+ lymphocytes
expressed low levels of Granzyme B (Fig. 3B), and Treg were
completely devoid of Granzyme B expression.
CTLA-4 has been identified as an effector molecule mediating
suppression by Tregs [13], and virtually all Treg in the tumors did
express CTLA-4, while conventional CD4
+ T cells had a lower
and more varied expression of CTLA-4 (Fig. 3C). The mean
fluorescence intensity (MFI) showed that Treg had more CTLA-4
per cell than conventional CD4
+ T cells, both in the tumor and in
the unaffected tissue (Fig. 3D). On conventional T cells, CTLA-4
is increased in the later stages of T cell activation, and mediates
down-regulated activity of the T cell expressing it [30]. There was,
however, no significant difference in the CTLA-4 expression by
tumor derived conventional CD4
+ T cells than by corresponding
cells from unaffected tissue (Fig. 3D).
Lymphocyte and endothelial adhesion molecules in
tumor and unaffected mucosa
To better understand the homing mechanisms involved in T cell
migration to colon tumors we examined homing receptor expression
on CD4
+,C D 8
+ LPL and Treg. These studies showed a significantly
decreased (p,0.05)expressionofthe mucosalhoming receptora4b7
onCD4
+cellsintumortissuecomparedtounaffectedtissue(Fig.4A).
On the other hand, integrin aEb7, that serves to attach lymphocytes
toE-cadherin onepithelialcells,butalsohasbeenimplicated inTreg
function [31,32], was expressed by more CD4
+ tumor infiltrating T
cells than CD4
+T cellsinunaffectedmucosa(p,0.05).The CD8
+T
cell expression of aEb7 was much higher than in CD4
+ Tc e l l s ,
probably reflecting the eventual intraepithelial position of many
Lymphocyte Recruitment to Colon Tumors
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+ T cells. Interestingly, there was also a significant (p,0.05)
increase in aEb7 expression on tumor infiltrating Treg compared to
Treginunaffectedtissue(Fig.4B),eventhoughTregwereneverseen
in the epithelium by IHC.
L-selectin is used as a homing receptor for secondary lymphoid
organs,butis alsoupregulated onT cellsmigratingtogastrictumors
[17]. In colon cancer patients, however, there was no consistent
difference in the frequencies of L-selectin
+ conventional T cells or
Treg in the tumor and in the surrounding tissue (data not shown).
Real time PCR demonstrated that MAdCAM-1 expression was
significantly reduced in the tumor compared to the unaffected
tissue (Fig. 5A). These results were confirmed by immunohisto-
chemistry, showing a lower density of MAdCAM-1
+ vessels in the
tumor-associated mucosa (Fig. 5B). PNAd, on the other hand
could not be detected at all in the colon lamina propria, neither in
tumor nor in the unaffected mucosa.
Chemokine receptor expression on LPL from tumor and
unaffected mucosa
Flow cytometry analyses showed that CXCR3, mainly ex-
pressed by Th1 cells and CTL, was present on significantly fewer
CD4
+ and CD8
+ LPL (p,0.01) in the tumor tissue compared to
Figure 1. Treg frequencies in tumor and unaffected mucosa. The frequencies of CD4
+CD25
high putative Treg in tumor associated and
unaffected mucosa from colon cancer patients were investigated using flow cytometry. (A) Paired individual frequencies of CD4
+CD25
hiputative Tregs
among all CD4
+ T cells from 17 patients, and an example of CD4 and CD25 staining in one individual. (B) Intracellular FOXP3 and surface CD127
staining of CD25
hi cells in the tumor from one individual. (C) Frequencies of CD4
+CD25
int T cells among all CD4
+ T cells in unaffected and tumor
mucosa. Connected lines represents data from the same individual. (D) Methylation status of the FOXP3 promoter region in FOXP3
+ and FOXP3
2
CD4
+ T cells sorted by flow cytometry from lamina propria cells isolated from unaffected and colon tumor tissue, as determined by Ms-SNUPE. Each
symbol represents data from one individual. *** p,0.001, Wilcoxon signed rank test.
doi:10.1371/journal.pone.0030695.g001
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only a trend towards decreasing frequencies of CXCR3
+ cells. In
contrast, CCR4, a chemokine receptor associated with Th2 and
Treg responses, was reciprocally expressed, i.e. there was a higher
frequency of CCR4
+ cells in CD4
+ conventional T cells and Treg
in the tumor than in the unaffected mucosa (Fig. 6). Finally, the
chemokine receptor CCR5, which is usually co-expressed with
CXCR3 on Th1 cells [33] was expressed in similar frequencies in
tumor and unaffected mucosa. This was also true for CXCR4,
CCR7, CCR9 and CCR10 (data not shown).
Chemokine concentrations in unaffected and tumor
mucosa
Finally, we examined the presence of chemokines signaling
through CCR4 and CXCR3 in protein extracts from tumor and
unaffected tissue to investigate if differences in chemokine
production could explain the altered T cell recruitment to tumor
tissues. Among the CCR4 binding chemokines, CCL17 (TARC)
concentrations were not significantly different while the concen-
tration of CCL22 (MDC) was significantly higher in tumors than
in unaffected tissues (3046320 pg CCL22/mg total protein and
1246111 pg/mg in tumor and unaffected tissue, respectively,
p,0.01), a finding that could explain the increased number of
CCR4
+ T cells in the tumor tissue. Among the CXCR3 binding
chemokines, CXCL9 (MIG) concentrations did not differ between
unaffected and tumor tissue. Surprisingly, CXCL10 (IP-10) and
CXCL11 (I-TAC) were both present in significantly higher
concentrations in the tumor tissue compare to unaffected mucosa
(70656 and 8.266.6 pg CXCL10/mg protein, respectively,
p,0.01 and 6726442 and 2116161 pg CXCL11/mg protein,
Figure 2. Immunofluorescence detection of T cell subsets in tumor and unaffected mucosa. The expression of surface CD4 (A and B) and
CD8 (C and D) in combination with intracellular FOXP3 was determined in unaffected (A and C) and tumor mucosa (B and D). E and F show isotype
control staining of the respective tissues, and G a close-up of FOXP3
+ cells (green nucleus) in close association with CD8
+ conventional T cells (red
surface staining) in a section of tumor mucosa.
doi:10.1371/journal.pone.0030695.g002
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+ T cells
and right hand panels show CD8
+ T cells. The expression of surface CD69 (A) and intracellular Granzyme B (B) was evaluated on conventional CD4
+
FOXP3
2 and CD8
+ T cells from the tumor and unaffected mucosa using flow cytometry. The frequencies of positive cells are given as the percentage
of all CD4
+ or CD8
+ cells, respectively. The expression of intracellular CTLA-4 (C) was evaluated in conventional CD4
+ FOXP3
2 T cells and the
frequencies of positive cells are given as the percentage of all CD4
+ T cells. C. (D) MFI for CTLA4 on conventional CD4
+FOXP3
2 T cells and putative
Tregs isolated from tumors and unaffected tissue. Graphs show paired individual values from 9 to 15 patients. (E) Ratios of CD8
+Granzyme B
+ cells to
CD4
+CD25
hi Treg cells among cells isolated from tumor and unaffected mucosa * p,0.05, ** p,0.01, *** p,0.001, Wilcoxon signed rank test.
doi:10.1371/journal.pone.0030695.g003
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+ CD4
+ and
CD8
+ T cells were present in significantly lower numbers in the
tumor compared to the unaffected tissue.
Discussion
Immunosuppressive Treg have been described in colon cancer
patients, and their numbers are increased in the tumor compared
to the surrounding unaffected mucosa [20,21,22,23]. However,
several recent studies show that high Treg frequencies actually
correlate with a better prognosis in colon cancer patients
[19,25,26]. We therefore aimed to define the subsets and putative
functions of Treg and conventional T cells that had migrated to
the tumor-associated colonic mucosa as well as the homing
mechanisms used by these cells. There was no change in the
frequencies of the CD4
+ or CD8
+ T lymphocytes and NK cells
between tumor-associated and unaffected mucosa, while the
frequencies of CD19
+ B cells were lower in the tumor. However,
T cell immunity is generally held to be more important for anti-
tumor responses than B cells [2], and we therefore analyzed the
activation stage of tumor-infiltrating T cells. Thus, we could
demonstrate reduced levels of recently activated CD69
+ T cells
and CD25
intCD4
+ T cells from tumor-associated colonic mucosa
compared to unaffected mucosa. A population of spleenic
CD4
+CD69
+, but CD25
2 and FoxP3
2, T cells with regulatory
activity has been described in tumor-bearing mice [34]. If a
corresponding population exists in human tumors, it would be
concealed among the CD4
+FOXP3
2CD69
+ T cells, but as this
population is substantially decreased in the tumors compared to
the unaffected mucosa, it may not be the most prominent local
Treg population. The reduced frequencies of CD69
+ and CD25
int
T cells were was accompanied by a significant increase in
CD4
+CD25
highFOXP3
+CD127
low Treg, confirming several recent
studies that used immunohistochemistry or PCR techniques to
detect Treg [19,21,22,23]. We could, however, extend the
previous findings by a more detailed characterization of tumor
associated Tregs. Thus, we demonstrate a complete demethylation
of the FOXP3 promoter in colon Treg from tumor tissue,
suggesting that the FOXP3
+ cells stably express FOXP3 as part of
an established Treg phenotype, and not due to recent activation of
conventional T cells.
Furthermore, some of the tumor-associated Treg express aEb7.
This integrin is used to anchor intraepithelial T cells to E-cadherin
on epithelial cells [31], but has also been implicated in Treg
function. A recent study by Siewert et al [32] shows that aEb7
+
Tregs are antigen experienced effector/memory cells with a high
turn-over rate. Such cells can develop in the periphery, and we
therefore speculate that the aEb7
+ Treg we detected may arise
locally in the tumor. Our results are in contrast to results from a
murine colon cancer model where approximately 90% of the
tumor-associated Treg expressed aEb7 [35]. However, frequen-
cies may vary due to species differences or the fact that the colon
tumor cells were injected subcutaneously in the murine model.
Finally, there was a high expression of CTLA-4 on Treg in the
human colon tumors. CTLA-4 on Treg is crucial for suppression
of autoimmunity and for efficient anti-tumor responses [13].
Figure 4. Expression of b7 integrins on T cells from tumor and unaffected mucosa. The expression of a4b7 (A) and aEb7 (B) was evaluated
on CD4
+ and CD8
+ T cells and Treg from the tumor and unaffected mucosa using flow cytometry. The frequencies of positive cells are given as the
percentage of all CD4
+ or CD8
+ cells, respectively. Graphs show paired individual values from 7 to 16 patients. * p,0.05, ** p,0.01, Wilcoxon signed
rank test.
doi:10.1371/journal.pone.0030695.g004
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active suppression of the anti-tumor immune response. Our
observations that Treg can be found in close proximity to
FOXP3
2CD4
+ and CD8
+ T cells in the tumor tissue and the
lower frequencies of activated conventional T cells in tumors
would also support this conclusion. It is also worth noting that
increased Treg frequencies were found in all tumors, irrespectively
of their differentiation grade and stage, as well as localization.
Taken together with the general view that there are several
variants of colon adenocarcinoma with different characteristics
accumulating in different parts of the colon [36], this indicates that
increased Treg frequencies is truly a general finding in all types of
colon cancer.
Recent studies, including more than 2 000 patients, have shown
that there is actually a positive correlation between higher Treg
frequencies in the tumor and increased survival [19,26,27].
However, when patients were grouped according to microsatellite
instability caused by deficiencies in mismatch repair (MMR) genes,
the positive correlation of Treg infiltration to survival in
multivariate analyses only remained in MMR-proficient patients
[26]. Furthermore, it was recently shown that high Treg
frequencies in colon tumors before treatment correlate to a better
overall survival and a better response to chemo- or chemoimmu-
notherapy [25]. These findings are not easily reconciled with our
observations indicating that Treg in colon tumors are active
immunosuppressive cells, and also with several other studies
showing that Treg infiltration in other types of solid tumors
correlate with poor prognosis [9,10,11]. However, in other studies,
Treg frequencies did not correlate to patient outcome in colon
cancer [28,37]. Instead, the ratio of CD3
+ lymphocytes to
FOXP3
+ Treg was a better predictor of disease-free survival than
tumor stage or lymph node spread [28], and high intratumoral
CD8
+ to Treg ratios also correlate to better survival [37]. Thus,
the ratio of Treg:effector T cells may be a better measure of the
net outcome of the immune response than just Treg frequencies
alone, as also suggested in gastric tumors [38]. The exact tissue
localization of Treg may also be important, since the location of
tumor infiltrating lymphocytes relative to the invading margin and
center of the tumor has been shown to be of prognostic value [39].
The patient material in the current study was relatively small, and
did not reveal any correlation between Treg frequencies and
survival during a 2–4.5 year follow-up period (data not shown).
Figure 5. Expression of MAdCAM-1 on endothelial cells in tumor and unaffected mucosa. The expression of MAdCAM-1 mRNA (A) and
protein (B) was evaluated in the tumor and unaffected mucosa real time PCR and immunohistochemistry respectively. The mRNA concentrations
were normalized against 18s mRNA. Graphs show paired individual values from 8 and 12 patients, and representative MAdCAM-1 staining in
unaffected mucosa (above) and tumor tissue (below). * p,0.05, Wilcoxon signed rank test.
doi:10.1371/journal.pone.0030695.g005
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Granzyme B, and this molecule also appears to contribute to Treg
mediated suppression [14]. In the present study, however, there
was no expression of Granzyme B at all in the Treg. On the other
hand, the presence of putative cytotoxic Granzyme B
+CD8
+ T
cells was increased in the tumor, and these cells may be a sign of
ongoing anti-tumor responses. Still, the ratio of CD8
+Granzyme
B
+ cells to CD4
+CD25
hi Treg cells was higher in the unaffected
then the tumor mucosa. In parallel to the increase in putative
effector CD8
+ CTL, there was an increase in CTLA-4
+ cells
within the CD4
+ conventional T cells. These cells are susceptible
to inhibition of effector functions through ligation of their CTLA-
4. Thus, several suppressive and anti-tumor responses seem to
exist side by side in the tumor, and the balance between them may
decide the final outcome of the tumor disease.
Even though the homing mechanisms used by lymphocytes to
enter healthy intestinal mucosa are relatively well-known, little is
known about lymphocyte homing to tumors in the gastrointestinal
tract. We could demonstrate that there are differences in T
lymphocyte homing mechanisms between tumor-associated mu-
cosa and unaffected mucosa in the colon. Previously, we have
shown that gastric cancer patients have a decreased expression of
MAdCAM-1 on tumor blood vessels, and that this was
accompanied by fewer a4b7
+ LPL in tumor mucosa compared
to unaffected mucosa [17]. Our present results extend these
findings to another major type of gastrointestinal tumors, showing
that also in colon tumors there are decreased frequencies of CD4
+
conventional T cells and Treg expressing a4b7 and a concomitant
decrease in MAdCAM-1 expression on the blood vessels. In
contrast to gastric cancer [18], we could never detect the L-selectin
ligand PNAd in the colon tissue.
Not only selectins and integrins contribute to lymphocyte
homing to mucosal surfaces, but the expression of chemokine
receptors on the lymphocyte surface is crucial for lymphocyte
homing. The chemokine receptor CXCR3 is expressed on
activated Th1-type lymphocytes and CTL and is abundant on
lymphocytes in the mucosa of normal intestine [40]. We show
here that the frequencies of CXCR3
+ conventional T cells are
significantly reduced in tumor compared to unaffected mucosa
f r o mt h es a m ep a t i e n t .C D 4
+ Th1 lymphocytes expressing
CXCR3 have been shown to be important for anti-tumor
responses [41,42], and the reduction in CXCR3
+ cells probably
mirrors a reduction of Th1 cells and CD8
+ CTL in the tumor
area [43,44]. The tumor evasion from CXCR3
+ cells is
probably not dependent on chemokine production by the tumor
since CXCR3 ligands CXCL10 and CXCL11 both are present
in higher concentrations in the tumor. The reduction in
CXCR3
+ cells in the tumor stand out in comparison with
expression of many other chemokine receptors, which were
similar in the tumor and unaffected mucosa. However, Treg and
conventional CD4
+ T cells expressing CCR4, which is primarily
expressed on Th2 type CD4
+ T cells and Treg [18,33,45] were
accumulating in the colon tumors. Our previous study also
showed increased CCR4 expression on gastric tumor-associated
Treg, accompanied by increased expression of CCR4 ligands
[18]. Here, significantly increased tissue concentrations of the
CCR4-ligand CCL22 were also found in colonic tumors, and
probably contribute to recruitment of CCR4
+ cells. Together,
these data suggest a selective exclusion of CXCR3
+ conven-
tional T cells from the tumor-associated mucosa, with a
concomitant recruitment of CCR4
+ Treg and conventional
CD4
+ Tc e l l s .
Figure 6. Chemokine receptor expression on T cells from tumor and unaffected mucosa. The expression of CXCR3 (A) and CCR4 (B) was
evaluated on conventional CD4
+ and CD8
+ T cells and Treg from the tumor and unaffected mucosa using flow cytometry. The frequencies of positive
cells are given as the percentage of all CD4
+ or CD8
+ cells, respectively. Graphs show paired individual values from 9 to 10 patients. * p,0.05,
** p,0.01, Wilcoxon signed rank test.
doi:10.1371/journal.pone.0030695.g006
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+CTLA-
4
hi Treg stably expressing FOXP3 in colon adenocarcinomas, and
close contact between Treg and conventional CD4
+ and CD8
+ T
cells. In parallel, frequencies of activated CD4
+ conventional T
cells with a Th1 profile were decreased in the tumor, while
granzyme B
+ putative cytotoxic CD8
+ cells were present. The
altered recruitment of Treg and conventional T cells was probably
dependent on changes in endothelial MAdCAM-1 expression and
tissue production of CCL22. Taken together, this change of the
local immunological balance favors suppressive mechanisms and
will probably diminish the ability of the immune response to
effectively attack the tumor.
Materials and Methods
Volunteers and collection of specimens
Thirthy-one patients undergoing partial colectomy at Sahl-
grenska University Hospital due to colon adenocarcinomas were
included in the study. Patient data is presented in table 1. The
study was approved by the Regional Board of Ethics in Medical
Research in west Sweden, and all volunteers gave a written
informed consent before participation. None of the patients had
undergone radiotheraphy or chemotheraphy for at least three
years prior to colectomy. During or immediately after colectomy, a
strip of tumor tissue was collected together with unaffected
mucosa, collected at least five centimeters away from the tumor.
Small pieces of the tissue were collected in RNAlater (Applied
Biosystems, Foster City, CA, USA) for isolation of RNA,
embedded in OCT for subsequent immunohistochemical analysis,
or snap frozen for protein extraction. Remaining tissue samples
were transported in cold PBS for isolation of LPL within one hour.
Since varying numbers of LPL could be retrieved from the tissue
from different patients, all analyses could not be performed in all
patients. In no case were patients eliminated from the assays, solely
the availability of cells determined which assays were performed.
Information on tumor stage, differentiation grade and metas-
tases was retrieved from the routine pathology report. Patients
were followed for 22 to 54 months after surgery (mean follow-up
time 32 months) and recurrence of the cancer disease or cancer
related death was recorded.
Isolation of LPL
LPL were isolated using collagenase/DNase enzymatic diges-
tion after removal of epithelial cells, as previously described [46].
This method gives an optimal yield of LPL with only small
amounts of epithelium remaining and preserves the surface
markers analysed in the study. The cell yield varied from person
to person, and therefore, all analyses could not be performed in all
individuals.
Flow cytometry analysis of intracellular and cell surface
markers
LPL from tumor and tumor-free mucosa were incubated with
fluorescently labeled antibodies for 30 min at 4uC. Fluorescent
antibodies used were labelled with PerCP/PECy5 (CD4, CD19),
APC (CD8, CD69), FITC (CD103, CD45RA, CD8, CXCR3,
CD127) and PE (L-selectin, CD25, CCR4, CD56, CCR5), and
were all from BD Biosciences (Erembodegem, Belgium). Integrin
a4b7 was detected with biotinylated mAb ACT-1 (kindly provided
by Dr. D. Picarella, Millenium Inc, Cambridge, MA). For
intracellular staining, surface markers were first labelled, the cells
fixed and then intracellular staining of FOXP3 and CTLA-4 was
performed using permeabilisation buffer (eBioscience, Hatfield,
UK) according to the protocol provided by the manufacturer.
After staining, cells were fixed in BD cellFIX
TM (BD Biosciences)
and analysis was carried out on a FACS Calibur using FlowJo
8.1.1 software.
RNA isolation and quantitative real time RT-PCR
Biopsies were homogenized by grinding with a pellet pestle
(Sigma-Aldrich) in an eppendorf tube in the presence of lysis buffer
(RNeasy Mini Kit, Qiagen, Solna, Sweden). The homogenized
tissue was added to a QIAshredder column (Qiagen) and total
RNA was extracted according to manufactures descriptions.
Extracted RNA was run on an 1% agarose gel to check RNA
integrity and concentration was measured on a NanoDrop ND-
1000 spectrophotometer, software version 2.5.1 and stored at
280uC until further use.
Preparation of cDNA was performed using the Omniscript kit
(Qiagen, Germany). For each 20 ml reaction, 500 ng total RNA
was used. Gene expression assays for MAdCAM-1 and 18s mRNA
were obtained from Applied Biosystems. For calculating the
difference in expression we used the comparative CT (threshold
cycle) method, also called 2
2DDCt. Data are presented as fold
change in mRNA expression, normalized to the 18s mRNA
Immunohistochemical detection of endothelial adhesion
molecules
For analysis of endothelial MAdCAM-1, PNAd and von
Willebrand factor (vWF) expression, 8 mm tissue sections were
cut onto glass slides and fixed in ice-cold acetone. Sections were
rehydrated in cold PBS followed by blocking with an avidin/biotin
kit (Molecular Probes, Eugene, OR, USA), and endogenous
peroxidase by glucose oxidase (Sigma-Aldrich). Sections were
incubated in PBS with anti-MAdCAM-1 (clone 10G3, kindly
donated by Professor Sirpa Jalkanen, University of Turku), anti-
pNAD (clone MECA-79, BD Biosciences), anti-vWF (clone F8/86,
DAKO, Glostrup, Denmark) or isotype control for 1 hour at room
temperature. Sections were then incubated with rabbit anti mouse
Ig-HRP (DAKO) or with biotinylated mouse anti rat IgM (BD
Table 1. Characteristics of the colon cancer patients included
in the study.
females males
n1 4 1 7
age 41–95 57–86
Tumor location ascending 8 12
transverse 3 1
descending 3 4
Differentiation grade high - 1
medium 8 12
low 3 1
mucinous 2 1
Tumor stage T1 - 2
T2 1 4
T3 10 5
T4 3 5
Lymph node spread 6 4
Distant metastases 1 1
doi:10.1371/journal.pone.0030695.t001
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Burlingame, CA, USA). All sections were developed with DAB
(Vector), counterstained in Meyer’s hematoxyline and mounted in
Mountex. Images were acquired using Zeiss Axiovision 4.7.2 and
analyzed in Biopix iQ 2.1.5.
Immunofluorescence detection of T cells in tissue
sections
T cells were detected in tissue sections by double staining with
anti-FOXP3 and anti-CD4 or CD8. Briefly, frozen sections were
fixed in 4% paraformaldehyde, washed with PBS containing 0.1%
saponin and endogenous biotin blocked as above. Thereafter,
slides were incubated with mouse anti-FOXP3 (clone 236A/E7)
[47] or isotype control (DAKO). Signal was detected and
amplified using tyramide-Alexa fluor 488 amplification (TSA kit,
Molecular probes). Sections were then incubated with mouse anti-
CD4 or CD8 (DAKO) followed by detection with goat-anti-mouse
IgG1 Alexa Fluor 594 (Molecular Probes) and mounted using
gold-anti-fade mounting medium containing DAPI (Molecular
Probes).
FOXP3 methylation analysis
LPL isolated from tumor and unaffected mucosa from 4 male
patients were stained for flow cytometric analysis of CD4 and
FOXP3 and sorted using a FACSAria cell sorter (BD) into
CD4
+FOXP3
+ and CD4
+FOXP3
2 populations. Genomic DNA
from these cells was isolated and bisulphite converted using an EZ
DNA methylation kit (ZYMO research, Orange, CA). The
FOXP3 promoter region was amplified by PCR, and the PCR
product was then subjected to methylation-sensitive single
nucleotide primer-extension analysis (Ms-SNUPE) by using an
ABI prism SNaP shotTM multiplex kit (Applied Biosystems) as
recently described [48]. Finally, the samples were subjected to
capillary electrophoresis on an ABI prism 3730 genetic analyzer,
and the results analyzed by using the Gene mapper V3.7 software.
Protein extraction and detection of chemokines
Proteins were extracted from biopsies as previously described
[49]. CXCL11, CCL17, and CCL22 concentrations were
determined by Duoset ELISA (R&D systems, Abingdon, United
Kingdom). CXCL9 and CXCL10 were detected using cytometric
bead array chemokine analysis (BD Biosciences). Total protein
concentration was measured using the BCA protein assay
(Thermo Fisher Scientific, Go ¨teborg, Sweden) following desalting
on Zeba
TM micro desalt spin columns (Thermo Fisher Scientific)
and chemokine concentrations were adjusted to total protein
concentrations.
Statistical analysis
All statistical analyses were carried out in SPSS 14.0 or PRISM
using the Wilcoxon signed rank test. P values less than 0.05 were
considered significant.
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